Logo image of TNYA

TENAYA THERAPEUTICS INC (TNYA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TNYA - US87990A1060 - Common Stock

0.85 USD
-0.51 (-37.5%)
Last: 12/12/2025, 8:04:51 PM
0.869 USD
+0.02 (+2.24%)
After Hours: 12/12/2025, 8:04:51 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to TNYA. TNYA was compared to 529 industry peers in the Biotechnology industry. While TNYA seems to be doing ok healthwise, there are quite some concerns on its profitability. TNYA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TNYA had negative earnings in the past year.
TNYA had a negative operating cash flow in the past year.
In the past 5 years TNYA always reported negative net income.
In the past 5 years TNYA always reported negative operating cash flow.
TNYA Yearly Net Income VS EBIT VS OCF VS FCFTNYA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

TNYA has a Return On Assets of -89.94%. This is in the lower half of the industry: TNYA underperforms 72.50% of its industry peers.
The Return On Equity of TNYA (-113.94%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -89.94%
ROE -113.94%
ROIC N/A
ROA(3y)-69.92%
ROA(5y)-51.76%
ROE(3y)-86.5%
ROE(5y)-62.63%
ROIC(3y)N/A
ROIC(5y)N/A
TNYA Yearly ROA, ROE, ROICTNYA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

TNYA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNYA Yearly Profit, Operating, Gross MarginsTNYA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

TNYA has more shares outstanding than it did 1 year ago.
TNYA has more shares outstanding than it did 5 years ago.
TNYA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TNYA Yearly Shares OutstandingTNYA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
TNYA Yearly Total Debt VS Total AssetsTNYA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -6.48, we must say that TNYA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.48, TNYA is doing worse than 66.48% of the companies in the same industry.
TNYA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.48
ROIC/WACCN/A
WACCN/A
TNYA Yearly LT Debt VS Equity VS FCFTNYA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 4.64 indicates that TNYA has no problem at all paying its short term obligations.
TNYA has a Current ratio of 4.64. This is comparable to the rest of the industry: TNYA outperforms 52.73% of its industry peers.
A Quick Ratio of 4.64 indicates that TNYA has no problem at all paying its short term obligations.
TNYA has a Quick ratio (4.64) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.64
Quick Ratio 4.64
TNYA Yearly Current Assets VS Current LiabilitesTNYA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

TNYA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.83%, which is quite impressive.
EPS 1Y (TTM)45.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 48.82% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y49.39%
EPS Next 2Y25.04%
EPS Next 3Y26.92%
EPS Next 5Y48.82%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TNYA Yearly Revenue VS EstimatesTNYA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
TNYA Yearly EPS VS EstimatesTNYA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TNYA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNYA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNYA Price Earnings VS Forward Price EarningsTNYA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNYA Per share dataTNYA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

TNYA's earnings are expected to grow with 26.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.04%
EPS Next 3Y26.92%

More info and screens

0

5. Dividend

5.1 Amount

TNYA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

TENAYA THERAPEUTICS INC

NASDAQ:TNYA (12/12/2025, 8:04:51 PM)

After market: 0.869 +0.02 (+2.24%)

0.85

-0.51 (-37.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-02 2026-03-02/amc
Inst Owners23.39%
Inst Owner Change4.59%
Ins Owners0.66%
Ins Owner Change-2.4%
Market Cap141.53M
Revenue(TTM)N/A
Net Income(TTM)-94.42M
Analysts84
Price Target10.35 (1117.65%)
Short Float %11.88%
Short Ratio5.09
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.74%
Min EPS beat(2)20.39%
Max EPS beat(2)45.1%
EPS beat(4)3
Avg EPS beat(4)13.35%
Min EPS beat(4)-23.84%
Max EPS beat(4)45.1%
EPS beat(8)7
Avg EPS beat(8)13.25%
EPS beat(12)11
Avg EPS beat(12)14.22%
EPS beat(16)12
Avg EPS beat(16)9.52%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)1.56%
EPS NQ rev (3m)1.56%
EPS NY rev (1m)4.15%
EPS NY rev (3m)6.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.71
P/tB 1.71
EV/EBITDA N/A
EPS(TTM)-0.78
EYN/A
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0
BVpS0.5
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -89.94%
ROE -113.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.92%
ROA(5y)-51.76%
ROE(3y)-86.5%
ROE(5y)-62.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.75%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.64
Quick Ratio 4.64
Altman-Z -6.48
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)115.07%
Cap/Depr(5y)317.48%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next Y49.39%
EPS Next 2Y25.04%
EPS Next 3Y26.92%
EPS Next 5Y48.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.87%
EBIT Next 3Y1.25%
EBIT Next 5Y-9.35%
FCF growth 1Y29.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.69%
OCF growth 3YN/A
OCF growth 5YN/A

TENAYA THERAPEUTICS INC / TNYA FAQ

Can you provide the ChartMill fundamental rating for TENAYA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to TNYA.


What is the valuation status for TNYA stock?

ChartMill assigns a valuation rating of 1 / 10 to TENAYA THERAPEUTICS INC (TNYA). This can be considered as Overvalued.


How profitable is TENAYA THERAPEUTICS INC (TNYA) stock?

TENAYA THERAPEUTICS INC (TNYA) has a profitability rating of 0 / 10.